AMGN vs. GILD, MRNA, PFE, ISRG, SYK, ELV, SNY, MDT, ABT, and VRTX
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE), Intuitive Surgical (ISRG), Stryker (SYK), Elevance Health (ELV), Sanofi (SNY), Medtronic (MDT), Abbott Laboratories (ABT), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
Amgen currently has a consensus price target of $296.95, indicating a potential upside of 9.99%. Gilead Sciences has a consensus price target of $83.87, indicating a potential upside of 28.20%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.
Amgen has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
76.5% of Amgen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.5% of Amgen shares are held by company insiders. Comparatively, 0.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 3.3%. Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.7%. Amgen pays out 72.1% of its earnings in the form of a dividend. Gilead Sciences pays out 855.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
In the previous week, Gilead Sciences had 44 more articles in the media than Amgen. MarketBeat recorded 62 mentions for Gilead Sciences and 18 mentions for Amgen. Amgen's average media sentiment score of 0.44 beat Gilead Sciences' score of 0.22 indicating that Amgen is being referred to more favorably in the media.
Amgen has a net margin of 23.83% compared to Gilead Sciences' net margin of 1.76%. Amgen's return on equity of 154.27% beat Gilead Sciences' return on equity.
Gilead Sciences received 926 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.39% of users gave Gilead Sciences an outperform vote while only 72.50% of users gave Amgen an outperform vote.
Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Amgen beats Gilead Sciences on 13 of the 20 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
